Yüklüyor......
Developmental Therapeutics in Myeloproliferative Neoplasms
The unprecedented success of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in myelofibrosis provided much-needed impetus for clinical drug development for the Philadelphia chromosome negative myeloproliferative neoplasms (MPN). The survival benefit conferred by this agent, along with its marked e...
Kaydedildi:
| Yayımlandı: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5540010/ https://ncbi.nlm.nih.gov/pubmed/28760302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2017.02.014 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|